
|Articles|July 1, 2018
- Pharmaceutical Executive-07-01-2018
- Volume 38
- Issue 7
Pharmaceutical Executive, July 2018 Issue (PDF)
Click the title above to open the Pharmaceutical Executive July 2018 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 7 years ago
Opioid Litigation: Evading the Widening Crosshairsover 7 years ago
Patient & Customer-Centric Commercializationover 7 years ago
Compliance: The Critical Cog in Pharma Machineover 7 years ago
Gaining Ground with Stem Cells: Gil Van Bokkelen, Athersysover 7 years ago
A Seat at the Strategy Tableover 7 years ago
Regulatory Innovation Generates Breakthroughsover 7 years ago
China’s Biopharma Rise: Opportunities and ThreatsNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Lilly’s Orforglipron, Retatrutide Named as Defining GLP-1 Drugs of the Next Decade
2
Johnson & Johnson Reaches Agreement with Trump Administration, Continues $55 Billion US-Based Investment Plan
3
Roundup: Pharma’s Funding Surge Ahead of J.P. Morgan 2026
4
FDA Limits Regulations on Non-Medical Grade Wearable Fitness Devices
5




